IL17D and ovarian carcinoma: In addition, in the Gilks cohort (GSE3208), the expression of IL-17D was significantly lower in stage I and II ovarian cancer patients compared with stage III and IV ovarian cancer patients (P = 0.023; Fig. 5b).